Related Experiment Video
Updated: May 23, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3
Kirsten Sandvig1, Alicia Llorente
1Department of Biochemistry, Institute for Cancer Research, Oslo University Hospital- The Norwegian Radium Hospital, 0379 Oslo, Norway.
Abstract:
Cancer biomarkers are invaluable tools for cancer detection, prognosis, and treatment. Recently, microvesicles have appeared as a novel source for cancer biomarkers. We present here the results from a proteomic analysis of microvesicles released to the extracellular environment by the metastatic prostate cancer cell line PC-3. Using nanocapillary liquid chromatography-tandem mass spectrometry 266 proteins were identified with two or more peptide sequences. Further analysis showed that 16% of the proteins were classified as extracellular and that intracellular proteins were annotated in a variety of locations. Concerning biological processes, the proteins found in PC-3 cell-released microvesicles are mainly involved in transport, cell organization and biogenesis, metabolic process, response to stimulus, and regulation of biological processes. Several of the proteins identified (tetraspanins, annexins, Rab proteins, integrins, heat shock proteins, cytoskeletal proteins, 14-3-3 proteins) have previously been found in microvesicles isolated from other sources. However, some of the proteins seem to be more specific to the vesicular population released by the metastatic prostate cancer PC-3 cell line. Among these proteins are the tetraspanin protein CD151 and the glycoprotein CUB domain-containing protein 1. Interestingly, our results show these proteins are promising biomarkers for prostate cancer and therefore candidates for clinical validation studies in biological fluids.
Insights
Researchers identified novel prostate cancer biomarkers in microvesicles from PC-3 cells. These microvesicle proteins, including CD151, show promise for early cancer detection and clinical studies.
Area of Science:
- Proteomics
- Cancer Biology
- Extracellular Vesicles
Background:
- Cancer biomarkers are crucial for detection, prognosis, and treatment.
- Microvesicles are emerging as a significant source of novel cancer biomarkers.
Purpose of the Study:
- To perform a proteomic analysis of microvesicles released by the metastatic prostate cancer cell line PC-3.
- To identify potential novel biomarkers for prostate cancer detection and clinical validation.
Main Methods:
- Proteomic analysis using nanocapillary liquid chromatography-tandem mass spectrometry.
- Identification and classification of proteins within PC-3 cell-released microvesicles.
Main Results:
- 266 proteins were identified in PC-3 microvesicles.
- 16% of identified proteins were extracellular, involved in various biological processes.
- CD151 and glycoprotein CUB domain-containing protein 1 were identified as potentially specific biomarkers.
Conclusions:
- Proteomic analysis of PC-3 microvesicles revealed specific proteins as promising prostate cancer biomarkers.
- CD151 and glycoprotein CUB domain-containing protein 1 warrant further clinical validation studies.
